FDA slowed – slightly – its recent torrid pace of novel agent approvals, clearing two more new products to bring the 2017 count of new molecular entities and novel therapeutic biologics to 20.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?